Black Diamond Therapeutics (BDTX) Other Non Operating Income (2019 - 2026)

Black Diamond Therapeutics' Other Non Operating Income history runs 8 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• Quarterly Other Non Operating Income fell 15.31% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 19.97% YoY) and the FY2025 annual result came in at $5.8 million, down 16.45% from the prior year.
• Other Non Operating Income was $1.2 million for Q1 2026 at Black Diamond Therapeutics, down from $1.3 million in the prior quarter.
• Across five years, Other Non Operating Income topped out at $2.1 million in Q3 2024 and bottomed at -$234000.0 in Q1 2022.
• A 5-year average of $920411.8 and a median of $1.2 million in 2026 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2024 — Other Non Operating Income soared 2062.5% — and 2025, when it plunged 36.02%.
• Black Diamond Therapeutics' Other Non Operating Income stood at $115000.0 in 2022, then soared by 876.52% to $1.1 million in 2023, then jumped by 53.61% to $1.7 million in 2024, then fell by 24.06% to $1.3 million in 2025, then retreated by 8.4% to $1.2 million in 2026.
• Business Quant data shows BDTX's Other Non Operating Income at $1.2 million in Q1 2026, $1.3 million in Q4 2025, and $1.3 million in Q3 2025.